Carmel Pezaro

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

Yohann Loriot, Diletta Bianchini, E. Ileana et al. · Annals of Oncology · 2013 · 356 citations · Full text

Medicine, Oncology, Pharmacology +16

Tumor clone dynamics in lethal prostate cancer

Suzanne Carreira, Alessandro Romanel, Jane Goodall et al. · Science Translational Medicine · 2014 · 340 citations

Medicine, Cancer Biology, Oncology +17

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100

Juliet Richards, Ai Chiin Lim, C. R. M. Hay et al. · Cancer Research · 2012 · 261 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Janusz Mezynski, Carmel Pezaro, Diletta Bianchini et al. · Annals of Oncology · 2012 · 248 citations

Medicine, Oncology, Pharmacology +16

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Diletta Bianchini, David Lorente, Alejo Rodríguez‐Vida et al. · European Journal of Cancer · 2013 · 209 citations

Medicine, Oncology, Pharmacology +14